SCHEMBL3633928

SCHEMBL3633928

CCCC(=O)c1ccc(NCc2csc(-c3ccc(Cl)cc3)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RHOC P08134 1/20 0.49
RHOA P61586 1/20 0.49
TP53 P04637 6/20 0.48
MAPT P10636 4/20 0.48
GFER P55789 1/20 0.46
LMNA P02545 4/20 0.46
POLB P06746 1/20 0.45
SCD O00767 1/20 0.45
THRB P10828 1/20 0.44
RAB9A P51151 3/20 0.44
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
GAA P10253 1/20 0.44
ALDH1A1 P00352 1/20 0.42
FRK P42685 1/20 0.42
CAMK2B Q13554 1/20 0.42
CAMK2G Q13555 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3639184 0.89 HPGD (0.52) MAPTLMNARAB9AKDM4ENPC1
SCHEMBL3637928 0.88 SUCNR1 (0.49) MAPTLMNAPOLBSCDRAB9A
SCHEMBL3634440 0.86 FRK (0.58) RHOCRHOATP53MAPTLMNA
SCHEMBL3633399 0.81 TP53 (0.49) TP53MAPTLMNARAB9ANPC1
SCHEMBL3666322 0.77 ADORA2A (0.41) TP53MAPTLMNAPOLBRAB9A
SCHEMBL3635886 0.74 THRB (0.52) TP53MAPTGFERLMNATHRB
SCHEMBL21523880 0.73 THRB (0.72) TP53MAPTLMNAPOLBTHRB
SCHEMBL11621590 0.72 SMN1; SMN2 (0.70) MAPTLMNARAB9ANPC1SMN1; SMN2
SCHEMBL3638167 0.72 KDM4C (0.44) MAPTSMN1; SMN2GAAALDH1A1FRK
SCHEMBL3637335 0.72 MAPT (0.51) TP53MAPTLMNAPOLBTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9242933-B2 Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) AbbVie Deutschland GmbH & Co. KG (DE) 2016-01-26 US disclosed
EP-2167464-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) Abbott GmbH & Co. KG (DE) 2010-03-31 EP disclosed
WO-2008145616-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) ABBOTT GMBH & CO. KG (DE) 2008-12-04 WO disclosed
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2008-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300260-A1 HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) GRM2, GRIN2C, GRM1 RHOC 2751/4885RHOA 4253/4885TP53 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.